Objectives: There are few studies about survival in patients with Cystic Fibrosis (CF) under oxygen therapy (OT). Considering its clinical meaning and impact on patients’ lifestyle, we aimed to determine how OT is associated with known prognostic factors and with lung transplantation (LTx) and death (D). Methods:We considered patients ≤50 years registered in the ECFSPR from 2008 to 2017. An illness-death multi-state model was fitted, denoting LTx as intermediate state. Cox’s proportional hazard models were fitted using age as time scale and left truncation corresponding to age at entry into ECFSPR. Models were used to estimate transition intensities and OT hazard ratio (HR), adjusted for known prognostic factors (age, sex, insulin, Pseudomonas aeruginosa (Pa), Burkholderia cepacia (BC), BMI and FEV1% predicted). Results: 58576 patients were included in the analysis and 7627 (13%) had OT during the follow-up. 27587 (47.6%) were females, 35784 (61.1%) were <18 yrs old, 5228 (10.6%) had FEV1 <40%predicted, 5185 (9.5%) were underweight (BMI z score <−2), 6386 (10.9%) used insulin, 14037 (26.9%) had Pa, 1236 (2.4%) had BC. During the follow-up, 2509 patients had LTx and 3091 patients died: 2338 before and 753 after LTx. From the multi-state model, patients in OT have higher probability of having LTx (HR = 12.9, 95% CI: 11.6–14.4). The HRof death for patients in OT is 7.8 (95% CI: 6.9–8.7) before LTX, while it is 1.4 (95% CI: 1.2–1.7) after LTx. Conclusions: The need for oxygen therapy represents a turning point in patients’ life, decreasing their chances of survival, with implications in the post LTX period yet. UndoubtedlyOT should be considered as a marker of CF disease severity, and patients with a supplemental oxygen requirement should have prompt and fully clinical reassessment. Preventing respiratory failure with oxygen requirement remains one of the main goals of CF care.

Lung transplantation and mortality in patients with cystic fibrosis under oxygen therapy / S. Gambazza, F. Ambrogi, A. Zolin, A. Orenti. - In: JOURNAL OF CYSTIC FIBROSIS. - ISSN 1569-1993. - 19:Suppl. 2(2020 Jun), pp. P176.S106-P176.S106. ((Intervento presentato al 43. convegno ECFS European Cystic Fibrosis Conference nel 2020.

Lung transplantation and mortality in patients with cystic fibrosis under oxygen therapy

S. Gambazza
Primo
;
F. Ambrogi
Secondo
;
A. Zolin
Penultimo
;
A. Orenti
Ultimo
2020

Abstract

Objectives: There are few studies about survival in patients with Cystic Fibrosis (CF) under oxygen therapy (OT). Considering its clinical meaning and impact on patients’ lifestyle, we aimed to determine how OT is associated with known prognostic factors and with lung transplantation (LTx) and death (D). Methods:We considered patients ≤50 years registered in the ECFSPR from 2008 to 2017. An illness-death multi-state model was fitted, denoting LTx as intermediate state. Cox’s proportional hazard models were fitted using age as time scale and left truncation corresponding to age at entry into ECFSPR. Models were used to estimate transition intensities and OT hazard ratio (HR), adjusted for known prognostic factors (age, sex, insulin, Pseudomonas aeruginosa (Pa), Burkholderia cepacia (BC), BMI and FEV1% predicted). Results: 58576 patients were included in the analysis and 7627 (13%) had OT during the follow-up. 27587 (47.6%) were females, 35784 (61.1%) were <18 yrs old, 5228 (10.6%) had FEV1 <40%predicted, 5185 (9.5%) were underweight (BMI z score <−2), 6386 (10.9%) used insulin, 14037 (26.9%) had Pa, 1236 (2.4%) had BC. During the follow-up, 2509 patients had LTx and 3091 patients died: 2338 before and 753 after LTx. From the multi-state model, patients in OT have higher probability of having LTx (HR = 12.9, 95% CI: 11.6–14.4). The HRof death for patients in OT is 7.8 (95% CI: 6.9–8.7) before LTX, while it is 1.4 (95% CI: 1.2–1.7) after LTx. Conclusions: The need for oxygen therapy represents a turning point in patients’ life, decreasing their chances of survival, with implications in the post LTX period yet. UndoubtedlyOT should be considered as a marker of CF disease severity, and patients with a supplemental oxygen requirement should have prompt and fully clinical reassessment. Preventing respiratory failure with oxygen requirement remains one of the main goals of CF care.
Settore MED/01 - Statistica Medica
giu-2020
https://www-sciencedirect-com.pros.lib.unimi.it:2050/journal/journal-of-cystic-fibrosis/vol/19/suppl/S2
Article (author)
File in questo prodotto:
File Dimensione Formato  
ECFS 2020 Supplement JCF-112.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 41.16 kB
Formato Adobe PDF
41.16 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/745577
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact